280 related articles for article (PubMed ID: 26757093)
1. Drug test results as a predictor of retention among patients using buprenorphine in a comprehensive outpatient treatment program.
Campbell MD; Kolodner G; Spencer RA; DuPont RL
J Addict Dis; 2016; 35(4):315-324. PubMed ID: 26757093
[TBL] [Abstract][Full Text] [Related]
2. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
[TBL] [Abstract][Full Text] [Related]
3. Psychiatric Comorbidity and Substance Use Outcomes in an Office-Based Buprenorphine Program Six Months Following Hurricane Sandy.
Tofighi B; Grossman E; Goldfeld KS; Williams AR; Rotrosen J; Lee JD
Subst Use Misuse; 2015; 50(12):1571-8. PubMed ID: 26623697
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of 6 remote First Nations community-based buprenorphine programs in northwestern Ontario: Retrospective study.
Mamakwa S; Kahan M; Kanate D; Kirlew M; Folk D; Cirone S; Rea S; Parsons P; Edwards C; Gordon J; Main F; Kelly L
Can Fam Physician; 2017 Feb; 63(2):137-145. PubMed ID: 28209683
[TBL] [Abstract][Full Text] [Related]
5. Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention.
D'Onofrio G; Chawarski MC; O'Connor PG; Pantalon MV; Busch SH; Owens PH; Hawk K; Bernstein SL; Fiellin DA
J Gen Intern Med; 2017 Jun; 32(6):660-666. PubMed ID: 28194688
[TBL] [Abstract][Full Text] [Related]
6. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.
Cottrill CB; Matson SC
Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312
[No Abstract] [Full Text] [Related]
7. Compliance with buprenorphine medication-assisted treatment and relapse to opioid use.
Tkacz J; Severt J; Cacciola J; Ruetsch C
Am J Addict; 2012; 21(1):55-62. PubMed ID: 22211347
[TBL] [Abstract][Full Text] [Related]
8. Group medication management for buprenorphine/naloxone in opioid-dependent veterans.
Berger R; Pulido C; Lacro J; Groban S; Robinson S
J Addict Med; 2014; 8(6):415-20. PubMed ID: 25275875
[TBL] [Abstract][Full Text] [Related]
9. Changes in Quality of Life following Buprenorphine Treatment: Relationship with Treatment Retention and Illicit Opioid Use.
Mitchell SG; Gryczynski J; Schwartz RP; Myers CP; O'Grady KE; Olsen YK; Jaffe JH
J Psychoactive Drugs; 2015; 47(2):149-57. PubMed ID: 25950595
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine replacement therapy for adolescents with opioid dependence: early experience from a children's hospital-based outpatient treatment program.
Levy S; Vaughan BL; Angulo M; Knight JR
J Adolesc Health; 2007 May; 40(5):477-82. PubMed ID: 17448411
[TBL] [Abstract][Full Text] [Related]
11. Modeling longitudinal changes in buprenorphine treatment outcome for opioid dependence.
Saleh MI
Pharmacopsychiatry; 2014 Nov; 47(7):251-8. PubMed ID: 25321188
[TBL] [Abstract][Full Text] [Related]
12. A naturalistic study of predictors of retention in treatment among emerging adults entering first buprenorphine maintenance treatment for opioid use disorders.
Dayal P; Balhara YPS
J Subst Abuse Treat; 2017 Sep; 80():1-5. PubMed ID: 28755768
[TBL] [Abstract][Full Text] [Related]
13. Patterns of abstinence or continued drug use among methadone maintenance patients and their relation to treatment retention.
White WL; Campbell MD; Spencer RD; Hoffman HA; Crissman B; DuPont RL
J Psychoactive Drugs; 2014; 46(2):114-22. PubMed ID: 25052787
[TBL] [Abstract][Full Text] [Related]
14. The Effect of a Payer-Mandated Decrease in Buprenorphine Dose on Aberrant Drug Tests and Treatment Retention Among Patients with Opioid Dependence.
Accurso AJ; Rastegar DA
J Subst Abuse Treat; 2016 Feb; 61():74-9. PubMed ID: 26639639
[TBL] [Abstract][Full Text] [Related]
15. A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment.
Fingerhood MI; King VL; Brooner RK; Rastegar DA
Subst Abus; 2014; 35(2):122-6. PubMed ID: 24821346
[TBL] [Abstract][Full Text] [Related]
16. Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.
Stein BD; Pacula RL; Gordon AJ; Burns RM; Leslie DL; Sorbero MJ; Bauhoff S; Mandell TW; Dick AW
Milbank Q; 2015 Sep; 93(3):561-83. PubMed ID: 26350930
[TBL] [Abstract][Full Text] [Related]
17. Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program.
Weinstein ZM; Gryczynski G; Cheng DM; Quinn E; Hui D; Kim HW; Labelle C; Samet JH
Drug Alcohol Depend; 2018 Aug; 189():166-171. PubMed ID: 29958128
[TBL] [Abstract][Full Text] [Related]
18. Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial.
Schramm ZA; Leroux BG; Radick AC; Ventura AS; Klein JW; Samet JH; Saxon AJ; Kim TW; Tsui JI
Addict Sci Clin Pract; 2020 Jul; 15(1):30. PubMed ID: 32736660
[TBL] [Abstract][Full Text] [Related]
19. Initiating buprenorphine treatment for hospitalized patients with opioid dependence: A case series.
Suzuki J; DeVido J; Kalra I; Mittal L; Shah S; Zinser J; Weiss RD
Am J Addict; 2015 Jan; 24(1):10-4. PubMed ID: 25823630
[TBL] [Abstract][Full Text] [Related]
20. Primary care patient characteristics associated with completion of 6-month buprenorphine treatment.
Neumann AM; Blondell RD; Azadfard M; Nathan G; Homish GG
Addict Behav; 2013 Nov; 38(11):2724-8. PubMed ID: 23934003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
